HRP20110434T1 - Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 - Google Patents
Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 Download PDFInfo
- Publication number
- HRP20110434T1 HRP20110434T1 HR20110434T HRP20110434T HRP20110434T1 HR P20110434 T1 HRP20110434 T1 HR P20110434T1 HR 20110434 T HR20110434 T HR 20110434T HR P20110434 T HRP20110434 T HR P20110434T HR P20110434 T1 HRP20110434 T1 HR P20110434T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- amino
- pyrazolo
- pyridin
- diethyl
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 25
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- DEPWAGNOLISJQB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 DEPWAGNOLISJQB-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 238000011282 treatment Methods 0.000 claims abstract 4
- 208000026935 allergic disease Diseases 0.000 claims abstract 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 2
- 230000000172 allergic effect Effects 0.000 claims abstract 2
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims abstract 2
- 206010039083 rhinitis Diseases 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- -1 C1-2fluoroalkyl Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 101100006941 Caenorhabditis elegans sex-1 gene Proteins 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- BGGGGSRXEVBHTI-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide;hydrochloride Chemical compound Cl.C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 BGGGGSRXEVBHTI-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- PHCXFLVZSJXLCQ-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[4-(4-morpholin-4-ylbutoxy)butyl]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(CCCCOCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 PHCXFLVZSJXLCQ-UHFFFAOYSA-N 0.000 claims 1
- UVOMAWFRWZVSRS-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[4-(4-pyrrolidin-1-ylbutoxy)butyl]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(CCCCOCCCCN2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 UVOMAWFRWZVSRS-UHFFFAOYSA-N 0.000 claims 1
- LQXPAXAIHLXYGQ-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[4-[4-[2-hydroxyethyl(methyl)amino]butoxy]butyl]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(CCCCOCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 LQXPAXAIHLXYGQ-UHFFFAOYSA-N 0.000 claims 1
- PCOQMMAGXDJXFT-SSEXGKCCSA-N 4-[[1,6-diethyl-5-[[[4-[8-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 PCOQMMAGXDJXFT-SSEXGKCCSA-N 0.000 claims 1
- PCOQMMAGXDJXFT-PMERELPUSA-N 4-[[1,6-diethyl-5-[[[4-[8-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 PCOQMMAGXDJXFT-PMERELPUSA-N 0.000 claims 1
- SPESJTHXLGHPOW-UHFFFAOYSA-N 4-[[1,6-diethyl-5-[[[4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzoyl]amino]methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCN(C(N)=O)CC1 SPESJTHXLGHPOW-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 229910005965 SO 2 Inorganic materials 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- QGZWUSODSJBHDB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-2-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=CC=C(NC(=O)CCCCCCCN(C)CCO)C=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 QGZWUSODSJBHDB-UHFFFAOYSA-N 0.000 claims 1
- JIHFKHSXPSMWSO-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=CC(NC(=O)CCCCCCCN(C)CCO)=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 JIHFKHSXPSMWSO-UHFFFAOYSA-N 0.000 claims 1
- UWBGOPUYNYLDRM-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-(8-morpholin-4-yloctanoylamino)benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 UWBGOPUYNYLDRM-UHFFFAOYSA-N 0.000 claims 1
- BEPDHRGYGYZEND-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-(8-morpholin-4-yloctyl)benzamide Chemical compound C=1C=C(CCCCCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 BEPDHRGYGYZEND-UHFFFAOYSA-N 0.000 claims 1
- LTPXTKORBUECMF-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-(8-pyrrolidin-1-yloctanoylamino)benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 LTPXTKORBUECMF-UHFFFAOYSA-N 0.000 claims 1
- YDCZHFGZHRPCBD-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[10-[2-hydroxyethyl(methyl)amino]decanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 YDCZHFGZHRPCBD-UHFFFAOYSA-N 0.000 claims 1
- ZRFLKCUWKNHLBE-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[11-[2-hydroxyethyl(methyl)amino]undecanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 ZRFLKCUWKNHLBE-UHFFFAOYSA-N 0.000 claims 1
- HNZYCJSOXTZPFW-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[4-(4-morpholin-4-ylbutoxy)butyl]benzamide Chemical compound C=1C=C(CCCCOCCCCN2CCOCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HNZYCJSOXTZPFW-UHFFFAOYSA-N 0.000 claims 1
- HOKINZWWJXHPBQ-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[4-(4-pyrrolidin-1-ylbutoxy)butyl]benzamide Chemical compound C=1C=C(CCCCOCCCCN2CCCC2)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HOKINZWWJXHPBQ-UHFFFAOYSA-N 0.000 claims 1
- VJPSYBYOJJNRCL-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[4-[4-[2-hydroxyethyl(methyl)amino]butoxy]butyl]benzamide Chemical compound C=1C=C(CCCCOCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 VJPSYBYOJJNRCL-UHFFFAOYSA-N 0.000 claims 1
- HWXCFWXSIMAGRN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[6-[2-hydroxyethyl(methyl)amino]hexanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 HWXCFWXSIMAGRN-UHFFFAOYSA-N 0.000 claims 1
- WNZVGXGWURJHEN-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[7-[2-hydroxyethyl(methyl)amino]heptanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 WNZVGXGWURJHEN-UHFFFAOYSA-N 0.000 claims 1
- MDKFYYZQPFHXSN-SSEXGKCCSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 MDKFYYZQPFHXSN-SSEXGKCCSA-N 0.000 claims 1
- MDKFYYZQPFHXSN-PMERELPUSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN2[C@@H](CCC2)COC)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 MDKFYYZQPFHXSN-PMERELPUSA-N 0.000 claims 1
- SWOQFOQBQPKIBC-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octyl]benzamide Chemical compound C=1C=C(CCCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 SWOQFOQBQPKIBC-UHFFFAOYSA-N 0.000 claims 1
- FYSISNCELBVBIX-UHFFFAOYSA-N n-[[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 FYSISNCELBVBIX-UHFFFAOYSA-N 0.000 claims 1
- XMANGTFEUXAABH-UHFFFAOYSA-N n-[[1-ethyl-6-methyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC1=C(C)N=C2N(CC)N=CC2=C1NC1CCOCC1 XMANGTFEUXAABH-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0615286A GB0615286D0 (en) | 2006-08-01 | 2006-08-01 | Compounds |
| GB0706790A GB0706790D0 (en) | 2007-04-05 | 2007-04-05 | Compounds |
| GB0714815A GB0714815D0 (en) | 2007-07-30 | 2007-07-30 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors |
| PCT/GB2007/002908 WO2008015416A1 (en) | 2006-08-01 | 2007-07-31 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110434T1 true HRP20110434T1 (hr) | 2011-08-31 |
Family
ID=38996907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110434T HRP20110434T1 (hr) | 2006-08-01 | 2011-06-09 | Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8003663B2 (pl) |
| EP (1) | EP2046787B1 (pl) |
| JP (1) | JP2009545579A (pl) |
| AT (1) | ATE504586T1 (pl) |
| AU (1) | AU2007280214A1 (pl) |
| CA (1) | CA2659539A1 (pl) |
| CL (1) | CL2007002349A1 (pl) |
| CY (1) | CY1111625T1 (pl) |
| DE (1) | DE602007013762D1 (pl) |
| DK (1) | DK2046787T3 (pl) |
| HK (1) | HK1127603A1 (pl) |
| HR (1) | HRP20110434T1 (pl) |
| NZ (1) | NZ574533A (pl) |
| PL (1) | PL2046787T3 (pl) |
| PT (1) | PT2046787E (pl) |
| SI (1) | SI2046787T1 (pl) |
| TW (1) | TW200840818A (pl) |
| WO (2) | WO2008015416A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2046787T3 (da) * | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
| KR20120006059A (ko) * | 2009-04-17 | 2012-01-17 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-아미노-1,3,3,5,5-펜타메틸사이클로헥산 메실레이트의 합성 |
| AR081377A1 (es) | 2010-05-10 | 2012-08-29 | Gilead Sciences Inc | Compuestos de pirazolopiridina bifuncionales |
| EP2605773A1 (en) * | 2010-08-19 | 2013-06-26 | Blanchette Rockefeller Neurosciences, Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| EP2628730B1 (en) * | 2012-02-16 | 2017-12-06 | Noxell Corporation | Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| DE102015000626A1 (de) * | 2015-01-22 | 2016-07-28 | Kibion Gmbh | Verfahren zum Nachweis von Helicobacter Pylori |
| CN111732543A (zh) * | 2020-08-14 | 2020-10-02 | 浙江鼎龙科技有限公司 | 一种4,5-二氨基-1-（2-羟乙基）吡唑硫酸盐的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3200123A (en) | 1962-01-26 | 1965-08-10 | Richardson Merreil Inc | Imidazoquinolines |
| JPS4824396B1 (pl) | 1970-09-09 | 1973-07-20 | ||
| US4335121A (en) | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
| DE3927761C2 (de) | 1989-08-23 | 1997-11-27 | Huels Chemische Werke Ag | Verfahren zur Herstellung von Alkoxyalkylidenmalonsäureestern |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| EP0752853B1 (en) | 1993-03-10 | 2005-09-21 | Smithkline Beecham Corporation | Human brain phosphodiesterase |
| EP0689424B1 (en) | 1993-03-17 | 1998-10-14 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| JP2989010B2 (ja) | 1994-06-15 | 1999-12-13 | ザ、ウェルカム、ファンデーション、リミテッド | 酵素阻害剤 |
| EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| TR199802745T2 (xx) | 1996-06-17 | 1999-04-21 | Smithkline Beecham Plc | �kameli benzamid t�revleri ve bunlar�n ihtiya�lar� durdurucu veya engelleyici maddeler olarak kullan�lmas�. |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| BR9809047A (pt) | 1997-03-18 | 2000-08-01 | Smithkline Beecham Plc | Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes |
| AUPO622597A0 (en) | 1997-04-15 | 1997-05-08 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| JPH11174621A (ja) | 1997-10-08 | 1999-07-02 | Fuji Photo Film Co Ltd | 熱現像写真感光材料 |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| CA2347856C (en) | 1998-11-13 | 2009-02-17 | Jago Research Ag | Dry powder for inhalation |
| SI1158958T1 (sl) | 1999-03-05 | 2007-10-31 | Chiesi Farma Spa | Izboljĺ ani praĺ kasti farmacevtski sestavki za inhalacijo |
| CA2373510A1 (en) | 1999-05-12 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| CA2325358C (en) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| WO2002008221A2 (en) | 2000-07-20 | 2002-01-31 | Neurogen Corporation | Capsaicin receptor ligands |
| WO2002012265A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
| US20020193393A1 (en) | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
| GB0123951D0 (en) | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| GB0208608D0 (en) | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Composition |
| ES2298511T3 (es) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | Derivados de fenetanolamina. |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| PL375993A1 (pl) | 2002-09-16 | 2005-12-12 | Glaxo Group Limited | Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy |
| US20060205790A1 (en) | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
| PL377122A1 (pl) | 2002-10-28 | 2006-01-23 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| TW200811171A (en) | 2003-10-14 | 2008-03-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2005044354A1 (en) | 2003-11-03 | 2005-05-19 | Glaxo Group Limited | A fluid dispensing device |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| US20070111995A1 (en) * | 2003-12-19 | 2007-05-17 | Allen David G | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors |
| GB0405937D0 (en) * | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| WO2005090352A1 (en) | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
| TWI363759B (en) | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| ATE503756T1 (de) | 2005-09-29 | 2011-04-15 | Glaxo Group Ltd | Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren |
| DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
-
2007
- 2007-07-31 DK DK07766400.1T patent/DK2046787T3/da active
- 2007-07-31 JP JP2009522327A patent/JP2009545579A/ja active Pending
- 2007-07-31 US US11/831,325 patent/US8003663B2/en not_active Expired - Fee Related
- 2007-07-31 DE DE602007013762T patent/DE602007013762D1/de active Active
- 2007-07-31 US US12/375,685 patent/US20090325952A1/en not_active Abandoned
- 2007-07-31 AU AU2007280214A patent/AU2007280214A1/en not_active Abandoned
- 2007-07-31 AT AT07766400T patent/ATE504586T1/de active
- 2007-07-31 EP EP07766400A patent/EP2046787B1/en active Active
- 2007-07-31 WO PCT/GB2007/002908 patent/WO2008015416A1/en active Application Filing
- 2007-07-31 SI SI200730620T patent/SI2046787T1/sl unknown
- 2007-07-31 PT PT07766400T patent/PT2046787E/pt unknown
- 2007-07-31 PL PL07766400T patent/PL2046787T3/pl unknown
- 2007-07-31 CA CA002659539A patent/CA2659539A1/en not_active Abandoned
- 2007-07-31 NZ NZ574533A patent/NZ574533A/en not_active IP Right Cessation
- 2007-08-01 WO PCT/GB2007/002935 patent/WO2008015437A1/en active Application Filing
- 2007-08-01 US US12/375,695 patent/US20090318494A1/en not_active Abandoned
- 2007-08-13 CL CL200702349A patent/CL2007002349A1/es unknown
- 2007-08-22 TW TW096131112A patent/TW200840818A/zh unknown
-
2009
- 2009-07-22 HK HK09106718.9A patent/HK1127603A1/xx not_active IP Right Cessation
-
2011
- 2011-06-09 HR HR20110434T patent/HRP20110434T1/hr unknown
- 2011-06-28 CY CY20111100623T patent/CY1111625T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ574533A (en) | 2011-05-27 |
| EP2046787B1 (en) | 2011-04-06 |
| CL2007002349A1 (es) | 2008-10-10 |
| SI2046787T1 (sl) | 2011-07-29 |
| PT2046787E (pt) | 2011-06-15 |
| WO2008015437A1 (en) | 2008-02-07 |
| DK2046787T3 (da) | 2011-07-18 |
| DE602007013762D1 (de) | 2011-05-19 |
| WO2008015416A1 (en) | 2008-02-07 |
| US8003663B2 (en) | 2011-08-23 |
| PL2046787T3 (pl) | 2011-10-31 |
| TW200840818A (en) | 2008-10-16 |
| ATE504586T1 (de) | 2011-04-15 |
| AU2007280214A1 (en) | 2008-02-07 |
| US20090318494A1 (en) | 2009-12-24 |
| JP2009545579A (ja) | 2009-12-24 |
| US20080058369A1 (en) | 2008-03-06 |
| HK1127603A1 (en) | 2009-10-02 |
| EP2046787A1 (en) | 2009-04-15 |
| CA2659539A1 (en) | 2008-02-07 |
| US20090325952A1 (en) | 2009-12-31 |
| CY1111625T1 (el) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110434T1 (hr) | Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4 | |
| JP2014037426A5 (pl) | ||
| ES2776654T3 (es) | Composición farmacéutica para administración oral que comprende un modulador de P2X7 | |
| JP6684552B2 (ja) | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン | |
| WO2004024728A3 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| JP6294953B2 (ja) | Ｐ２ｘ７調節物質 | |
| JP2017511365A5 (pl) | ||
| HRP20170896T1 (hr) | Derivati pirimidina | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| RU2015127079A (ru) | Соединения, используемые в качестве ингибиторов киназы atr | |
| TW200500364A (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| JP2009522206A (ja) | へテロ環ヤヌスキナーゼ３阻害剤 | |
| CA2565852A1 (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| JP2014531458A5 (pl) | ||
| RU2014106020A (ru) | Ингибиторы втк | |
| EA200970852A1 (ru) | Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| JP2013500247A5 (pl) | ||
| JP2017515848A5 (pl) | ||
| RU2014131367A (ru) | Соединения тиенопиримидина | |
| TW202411229A (zh) | 用於治療發炎性病症之新穎化合物及其醫藥組合物 | |
| WO2021032582A1 (en) | Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| AU2022240929A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| AU2006283511A1 (en) | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use |